ten Bosch John Roderick sold $132K of BLLN

ten Bosch John Roderick (SVP of Laboratory Operations) sold 1,417 shares of BillionToOne, Inc. (BLLN) at $92.86 ($0.13M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Aug 12, 2026, 10:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The only new information is the specific sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and modest dollar amount reduce expected price impact.

03

What to watch

The filing does not disclose any change in business outlook, guidance, or material events; the sale size is relatively small versus typical institutional flows.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for BillionToOne, Inc.

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

BillionToOne (BLLN) disclosed an SVP sale of 1,417 shares at $92.86 on a 10b5-1 plan, totaling about $131.6K.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and small.

Evidence & confidence

Form 4 shows a modest, planned sale by an officer, not a new operational or financial disclosure.

Market effects

No sector read-through is provided beyond a single planned insider transaction.

None indicated.

None indicated.

Counterpoint

Insider selling under a 10b5-1 plan can be purely liquidity-driven and may not reflect negative expectations.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • ten Bosch John Roderick

    SVP of Laboratory Operations who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.